Research Set to Expand as Federal Government Considers Rescheduling Cannabis from Schedule I to Schedule III with Phil Johnston Johnston Associates TRANSCRIPT
Release Date: 05/13/2024
Why Hospital Printers Have Become Targets for Cybercriminals with Jim LaRoe Symphion TRANSCRIPT
Empowered Patient Podcast
Jim LaRoe, CEO of Symphion, highlights an often overlooked cybersecurity threat posed by network-connected printers in a hospital setting. Modern printers are complex devices with numerous features that create vulnerabilities and potential access points to patient and hospital data for cybercriminals, yet they are generally managed outside of the IT security environment. The first step in ensuring printer security is to determine the number of printing devices on the network, their locations, and their configurations. Additionally, it is essential to ask the IT team to demonstrate...
info_outline
Why Hospital Printers Have Become Targets for Cybercriminals with Jim LaRoe Symphion
Empowered Patient Podcast
Jim LaRoe, CEO of Symphion, highlights an often overlooked cybersecurity threat posed by network-connected printers in a hospital setting. Modern printers are complex devices with numerous features that create vulnerabilities and potential access points to patient and hospital data for cybercriminals, yet they are generally managed outside of the IT security environment. The first step in ensuring printer security is to determine the number of printing devices on the network, their locations, and their configurations. Additionally, it is essential to ask the IT team to demonstrate...
info_outline
How Laboratory Robots Are Transforming Hydrogel Testing with Sinan Gölhan GelTech TRANSCRIPT
Empowered Patient Podcast
Sinan Gölhan, Founder and CEO of GelTech, describes the characteristics and applications for hydrogels, which are bio-friendly, super-absorbent materials similar to natural tissue. In cancer treatments, hydrogels offer a way to deliver chemotherapy drugs directly to a tumor, which can significantly increase the accuracy and efficacy of the drug. GelTech has developed a robotic instrument to streamline the time-consuming testing process for new hydrogel treatments, automating repetitive actions, reducing inconsistencies, and enabling 24/7 testing capabilities. Sinan explains, "You could think...
info_outline
How Laboratory Robots Are Transforming Hydrogel Testing with Sinan Gölhan GelTech
Empowered Patient Podcast
Sinan Gölhan, Founder and CEO of GelTech, describes the characteristics and applications for hydrogels, which are bio-friendly, super-absorbent materials similar to natural tissue. In cancer treatments, hydrogels offer a way to deliver chemotherapy drugs directly to a tumor, which can significantly increase the accuracy and efficacy of the drug. GelTech has developed a robotic instrument to streamline the time-consuming testing process for new hydrogel treatments, automating repetitive actions, reducing inconsistencies, and enabling 24/7 testing capabilities. Sinan explains, "You could think...
info_outline
Treating Autoimmune-Driven Dry Eye Disease with Immune Modulator with Elizabeth Jeffords Iolyx TRANSCRIPT
Empowered Patient Podcast
Elizabeth Jeffords, CEO and President of Iolyx Therapeutics, discusses dry eye disease and its connection to autoimmune conditions. The company's novel therapeutic topical immune modulator is designed to treat the root inflammation in the eye, which systemic drugs often fail to reach due to the blood-retina barrier. Patients with dry eye disease often have multiple comorbidities and are excluded from clinical trials, making this research even more significant in finding treatments for a growing population. Elizabeth explains, "Some people have physical dry eye, i.e., they have a dysfunction...
info_outline
Treating Autoimmune-Driven Dry Eye Disease with Immune Modulator with Elizabeth Jeffords Iolyx
Empowered Patient Podcast
Elizabeth Jeffords, CEO and President of Iolyx Therapeutics, discusses dry eye disease and its connection to autoimmune conditions. The company's novel therapeutic topical immune modulator is designed to treat the root inflammation in the eye, which systemic drugs often fail to reach due to the blood-retina barrier. Patients with dry eye disease often have multiple comorbidities and are excluded from clinical trials, making this research even more significant in finding treatments for a growing population. Elizabeth explains, "Some people have physical dry eye, i.e., they have a dysfunction...
info_outline
Using AI in Drug Development to Protect Brain Enzyme Linked to Parkinson’s Disease Progression with Gene Mack Gain Therapeutics TRANSCRIPT
Empowered Patient Podcast
Gene Mack, CEO and President of Gain Therapeutics, is combining AI-powered drug discovery with the development of allosteric modulators, drugs that bind to unique sites on proteins. The company's AI platform, Magellan, is crucial for accelerating drug discovery by reducing the time for computational screening of potential drug compounds. Their lead compound is showing promising results as a potential disease-modifying therapy for Parkinson's disease, aiming to halt the progression of the disease rather than just treating symptoms. Gene explains, "So allosteric modulators of protein,...
info_outline
Using AI in Drug Development to Protect Brain Enzyme Linked to Parkinson’s Disease Progression with Gene Mack Gain Therapeutics
Empowered Patient Podcast
Gene Mack, CEO and President of Gain Therapeutics, is combining AI-powered drug discovery with the development of allosteric modulators, drugs that bind to unique sites on proteins. The company's AI platform, Magellan, is crucial for accelerating drug discovery by reducing the time for computational screening of potential drug compounds. Their lead compound is showing promising results as a potential disease-modifying therapy for Parkinson's disease, aiming to halt the progression of the disease rather than just treating symptoms. Gene explains, "So allosteric modulators of protein,...
info_outline
Advancement in Abuse-Deterrent Opioids with Paul Howe Protega Pharmaceuticals TRANSCRIPT
Empowered Patient Podcast
Paul Howe, COO of Protega Pharmaceuticals, is focused on how abuse-deterrent technology can address the opioid crisis and the need for mandates for insurance coverage of safer abuse-deterrent formulations. The SentryBond technology was specifically designed for immediate-release opioids to make it difficult to manipulate pills for abuse via crushing, inhaling, or injecting. Protega partnered with software company Opus to offer a program that helps educate chronic pain patients, manage their treatment, and provides physicians with risk stratification data to improve care and reduce the...
info_outline
Advancement in Abuse-Deterrent Opioids with Paul Howe Protega Pharmaceuticals
Empowered Patient Podcast
Paul Howe, COO of Protega Pharmaceuticals, is focused on how abuse-deterrent technology can address the opioid crisis and the need for mandates for insurance coverage of safer abuse-deterrent formulations. The SentryBond technology was specifically designed for immediate-release opioids to make it difficult to manipulate pills for abuse via crushing, inhaling, or injecting. Protega partnered with software company Opus to offer a program that helps educate chronic pain patients, manage their treatment, and provides physicians with risk stratification data to improve care and reduce the...
info_outlinePhil Johnston, President and CEO of Johnston Associates, and an advisor to EO Care, the market leader in providing clinically-guided cannabis use. Phil discusses the potential for research from the reclassification of cannabis from a Schedule I drug to a Schedule III drug. With current Federal restrictions on cannabis, research has not been conducted on the potential therapeutic use for pain relief, depression, PTSD, and other conditions. With a change in classification, researchers can develop protocols, test different cannabis strains, run clinical trials, and determine dosage and form for therapies.
Phil explains, "So changing the Schedule from I to III is a game-changer because it's going to allow for research in the cannabis area in terms of dosage, what's the appropriate dosage, what kind of marijuana should be used for whatever ails you. There's a particular emphasis, of course, on pain relief and sleeplessness and depression. It appears that cannabis can have a very serious positive impact on those maladies, but we need much more research, and that's where we come in. That's what we're trying to focus on with EO Care."
"If you talk to any MD in the country, they'll tell you that they didn't learn anything about cannabis in medical school, and that was because of the Federal ban. And so there hasn't been a lot of research done. It's anecdotal at this point, such as my wife's situation, and what we need is for the Federal Government and the states to lead the way to make sure that there's funding for research and that medical schools are including that in their curricula. The research will involve what normally is involved with drugs, which is trials to determine exactly what the best treatments would be."
"Dosing is very important to figure out how much of it one needs, given whatever the specific problem is. And none of that research has been done in this country yet. Now, we're doing a sweep of international studies. It turns out that Canada, which legalized this a long time ago, has done trials and has some research, which we can adapt. However, that work has to be done, and it has to be done within medical institutions in the United States as well."
#MedicalCannabisAccessibility #MedicalCannabisClinicalResearch #MedicalCannabisCancerPatients #CannabisRescheduling #FutureofMedicalCannabis
